The indication for extended use, if approved, would allow the antiviral treatment to be given to more patients as coronavirus infections surge and healthcare systems are pressured by emerging, highly transmissible variants of the virus.
U.S.-based developer Gilead has submitted data to the European Medicines Agency (EMA), the watchdog said, adding that its human medicines committee...